Hudson Bay Capital Management LP Moon Lake Immunotherapeutics Transaction History
Hudson Bay Capital Management LP
- $28.9 Billion
- Q1 2025
A detailed history of Hudson Bay Capital Management LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 80,000 shares of MLTX stock, worth $3.12 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
80,000
Previous 7,500
966.67%
Holding current value
$3.12 Million
Previous $398,000
685.18%
% of portfolio
0.01%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
161Shares Held
55.3MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$770 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$331 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$116 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$108 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$57.7 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.44B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...